Report Publication Announcement • Feb 5, 2008
Report Publication Announcement
Open in ViewerOpens in native device viewer
On February 6, Tomas Puusepp, President & CEO of Elekta will present at Merrill Lynch Global Pharmaceuticals, Biotechnology & Medical Devices Conference in New York.
The presentation by Mr Puusepp will be held at 9.20-10.00am ET (15.20- 16.00 CET) and an audio only live webcast of the presentation and Q&A session will be available on:
http://www.veracast.com/webcasts/ml/globalpharma08/45203401.cfm
This link will be live just prior to the start of the presentation and will be available for on-demand replay within 24 hours.
Please note:
To access the webcast presentation, you will need Windows Media Player and/or Real Player installed on your computer. This event requires that you register prior to accessing any of the webcasts and requires that you have 'cookies' enabled on your browser.
******
For further information, please contact:
Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.
Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.
Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR and efficient management of clinical and patient data.
With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at www.elekta.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.